Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines
Nov 16, 2022•over 2 years ago
Amount Raised
$26 Million
Round Type
series a
Investors
Adjuvant CapitalRa Capital ManagementJanus Henderson Investors
Description
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
FundzWatch™ Score
74
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech